GENEVA, SWITZERLAND, 15 March 2017
Combioxin SA, a company dedicated to the development of novel anti-infective drugs, announced today that results from the first-in-human trial with CAL02 in patients with severe community-acquired pneumococcal pneumonia (CAL02-001 clinical trial) will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna in April. Dr Bruno François (University Hospital of Limoges, France) will present the results of this randomized multi-centre, double-blind, placebo-controlled trial, on 24 April 2017, at the oral session on New Agents for Bacterial Infection in Phase 2 and 3 Clinical Trials. This trial assesses the safety and efficacy of CAL02 (a broad-spectrum anti-virulence agent) in combination with standard of care to prevent clinical deterioration in patients who were hospitalised with severe pneumococcal pneumonia.
In addition to this oral presentation, Dr. Antonio Perez will present preclinical efficacy data of CAL02 against Gram-negative Pseudomonas aeruginosa (ECCMID 2017 – Poster session).
ABOUT THE TRIAL
Additional information about CAL02-001 can be found at:
https://clinicaltrials.gov/ct2/show/NCT02583373
CONTACT DETAILS
Combioxin SA – 8 rue de la Rôtisserie, 1204 Geneva, Switzerland
Email: info@combioxin.com
Website: http://www.combioxin.com
Combioxin SA, a company dedicated to the development of novel anti-infective drugs, announced today that results from the first-in-human trial with CAL02 in patients with severe community-acquired pneumococcal pneumonia (CAL02-001 clinical trial) will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna in April. Dr Bruno François (University Hospital of Limoges, France) will present the results of this randomized multi-centre, double-blind, placebo-controlled trial, on 24 April 2017, at the oral session on New Agents for Bacterial Infection in Phase 2 and 3 Clinical Trials. This trial assesses the safety and efficacy of CAL02 (a broad-spectrum anti-virulence agent) in combination with standard of care to prevent clinical deterioration in patients who were hospitalised with severe pneumococcal pneumonia.
In addition to this oral presentation, Dr. Antonio Perez will present preclinical efficacy data of CAL02 against Gram-negative Pseudomonas aeruginosa (ECCMID 2017 – Poster session).
ABOUT THE TRIAL
Additional information about CAL02-001 can be found at:
https://clinicaltrials.gov/ct2/show/NCT02583373
CONTACT DETAILS
Combioxin SA – 8 rue de la Rôtisserie, 1204 Geneva, Switzerland
Email: info@combioxin.com
Website: http://www.combioxin.com
